Health care stocks were mixed premarket Wednesday, as the Health Care Select Sector SPDR Fund (XLV) was down 0.1% and the iShares Biotechnology ETF (IBB) was 0.4% higher recently.
Novo Nordisk (NVO) is under investigation by Spain's ministry of health over its website communications on its weight-loss drug. The government body said the communications on the website "could be considered as covert advertising of prescription drugs, which is prohibited by current legislation," according to a translation of a June 19 statement. Shares of Novo Nordisk were more than 2% lower pre-bell.
Evotec (EVO) shares were up more than 3% after the company said it will join the NURTuRE-AKI consortium to establish a patient cohort for acute kidney injury.
Hims & Hers Health (HIMS) will continue offering low-cost weight-loss injections despite Novo Nordisk's decision to terminate their distribution partnership, Bloomberg reported, citing CEO Andrew Dudum. Shares of Hims & Hers Health were about 2% higher pre-bell.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.